ClinicalTrials.gg
RecruitingNCT07734116Updated Oct 6, 2026

A Study of ONO-4538HSC in Pediatric Patients With Malignant Solid Tumors and in Patients With Epithelioid Sarcoma.

A Phase 1/2 interventional study of ONO-4538HSC in Pediatric Malignant Solid Tumor and Epithelioid Sarcoma, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 15 sites in Japan. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2026; still recruiting 2 months later.
Updated Oct 6, 2026Site recruiting status changedStart date moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 20 studies in Sarcoma with a site in Japan — 7 open to participants now, 8 under way, none of them phase 3. Sarcoma · Japan.

Planned enrollment
12th of 19
50 · median 55
Started
2026
with 2 others
Phase 1/2
7 of 20
4 open now
Registered
20th of 20
by date

Among the 20 studies in Sarcoma with a site in Japan, this one is the 12th largest by planned enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2026, is one of 7 in phase 1/2, and was the 20th registered.

Sarcoma

1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.

Browse Sarcoma studies →

Open to participants now

7 of the 20 studies in Sarcoma with a site in Japan are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 301 Sarcoma studies recruiting now, 191 (63%) set no upper age limit and 83 (28%) stop at 75 or younger; 93 take children under 18; 12 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Sarcoma with a site in Japan, or all of them as a file.
02

Study summary

This is a multicenter, open-label, uncontrolled Phase I/II study to evaluate the efficacy, safety, and pharmacokinetics of ONO-4538HSC in pediatric patients with malignant solid tumors and in patients with epithelioid sarcoma, and to evaluate the tolerability in pediatric patients. The objective of this study is to explore the tolerability, safety, efficacy, and pharmacokinetics of ONO-4538HSC in patients with pediatric malignant solid tumors. The other objective is to exploratively investigate the efficacy and safety of ONO-4538HSC in patients with epithelioid sarcoma.

03

Conditions studied

  • Pediatric Malignant Solid Tumor and Epithelioid Sarcoma

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[Cohort of pediatric malignant solid tumor Tolerability evaluation part]

  1. Patients aged ≥ 12 to \< 18 years at the time of signing the form (ICF)
  2. Patients with radically/curatively unresectable advanced or solid tumor who are to or intolerant to standard treatment or for which no standard treatment is available.
  3. Patients with PS of 0 to 1

    [Cohort of pediatric malignant solid tumor Expansion part]

  4. Patients aged ≥ 12 to \< 18 years at the time of signing the informed consent form (ICF)
  5. Patients with unresectable tumors for whom nivolumab intravenous monotherapy is indicated in adults according to the package insert
  6. Patients who have at least 1 per guideline
  7. Patients with ECOG PS of 0 to 2

    [Cohort of Epithelioid Sarcoma]

  8. Patients aged ≥ 12 years of age at the time of signing the informed consent form (ICF). However, patients aged ≥ 12 to \< 18 years may be enrolled after tolerability is confirmed in the tolerability evaluation part in the cohort of pediatric malignant solid tumor.
  9. Patients who are refractory to or ineligible to at least 1 regimen of chemotherapy including doxorubicin for unresectable advanced or recurrent epithelioid sarcoma
  10. Patients who have at least 1 measurable lesion per RECIST guideline
  11. Patients with ECOG PS of 0 to 2

    [Common]

  12. ≥ 3 months at the time of enrollment

Exclusion criteria

Exclusion Criteria:

  1. Patients with current or previous severe reactions to antibody products
  2. Patients with primary central nervous system tumor
  3. Patients with brain or meningeal . However, patients who are asymptomatic and do not require treatment can be enrolled.
  4. Patients with multiple cancers
  5. Patients who have previously received antibody, anti-PD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, anti-CTLA-4 antibody, or other therapeutic antibodies or pharmacotherapies for regulation of T cells
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    ONO-4538HSC

    Drug: ONO-4538HSC

Interventions

  • DrugONO-4538HSC

    ONO-4538HSC will be administered subcutaneously once every 4 weeks.

06

What researchers measure

Primary outcomes

  1. Adverse events meeting protocol-defined criteria for a DLT

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: 28 days

  2. Serious adverse events

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: UP to 100 days after the last dose

  3. Adverse events

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: UP to 100 days after the last dose

  4. Response rate (central assessment)

    Cohort of Epithelioid Sarcoma

    Time frame: Through study completion, an average of 6 months

Secondary outcomes

  1. Serum concentration of nivolumab

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

  2. Response rate (investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  3. Progression-free survival (central assessment and investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  4. Disease control rate (central assessment and investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  5. Duration of response (central assessment and investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  6. Time to response (central assessment and investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  7. Best overall response (central assessment and investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  8. Maximum percent change from baseline in the sum of diameters of target lesions (central assessment and investigator assessment)

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  9. Changes in tumor markers over time

    Cohort of epithelioid sarcoma

    Time frame: Through study completion, an average of 6 months

  10. Adverse events

    Cohort of epithelioid sarcoma

    Time frame: UP to 100 days after the last dose

  11. Serum concentration of nivolumab

    Cohort of epithelioid sarcoma

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

Other outcomes

  1. Response rate (central assessmen and assessment by site investigator [hereinafter,investigator assessment])

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  2. Overall survival

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  3. Progression-free survival (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  4. Disease control rate (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  5. Duration of response (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  6. Time to response (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  7. Best overall response (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  8. Percent change from baseline in the sum of tumor diameters of target lesions (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  9. Maximum percent change from baseline in the sum of diameters of target lesions (central assessment and investigator assessment)

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  10. Changes in tumor markers over time

    Cohort of Patients with Pediatric Malignant Solid Tumor

    Time frame: Through study completion, an average of 6 months

  11. Analysis of efficacy, etc. with PD-L1 expression (measured at the central laboratory) and collected parameters

    Common to both cohorts

    Time frame: Screening

  12. Anti-nivolumab antibody

    Common to both cohorts

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

  13. Anti-rHuPH20 antibodies

    Common to both cohorts

    Time frame: Up to Cycle25 (each cycle is 28 days) and Post-treatment observation phase (28 days after the end of treatment phase)

07

Study locations

6 of 15 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Nov 2029, 38 months after the start.

Of 44 industry-sponsored phase 1/2 interventional studies under Sarcoma, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 43 and three quarters within 89. This study's planned 38 months is below that.

Counting every sponsor, half of 101 studies reached it within 62 months; a quarter within 45 and three quarters within 106.

Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Oct 6, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2026
First posted
Jul 29, 2026
StartActual
Sep 15, 2026was Aug 2026
Primary completionEst.
Nov 30, 2029
CompletionEst.
Feb 29, 2032
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added. 4 sites changed recruiting status (4 now recruiting)
Show 4 sites
  • Chiba University Hospital · Chiba, JapanNot yet recruiting→Recruiting
  • Kyushu University Hospital · Fukuoka, JapanNot yet recruiting→Recruiting
  • Kyoto University Hospital · Kyoto, JapanNot yet recruiting→Recruiting
  • Osaka International Cancer Institute · Osaka, JapanNot yet recruiting→Recruiting
Show 6 added (6 Japan)
  • National Cancer Center Hospital East · Kashiwa, Japan
  • Kanazawa University Hospital · Kanazawa, Japan
  • Mie University Hospital · Tsu, Japan
  • Tohoku University Hospital · Sendai, Japan
  • Okayama University Hospital · Okayama, Japan
  • Kindai University Hospital · Sakai, Japan
Oct 6, 2026
Start date
Aug 18, 2026→Sep 15, 2026
Oct 6, 2026
Show all 1 update
  1. Oct 6, 2026
    6 sites added. 4 sites changed recruiting status (4 now recruiting)
    Show 4 sites
    • Chiba University Hospital · Chiba, JapanNot yet recruiting→Recruiting
    • Kyushu University Hospital · Fukuoka, JapanNot yet recruiting→Recruiting
    • Kyoto University Hospital · Kyoto, JapanNot yet recruiting→Recruiting
    • Osaka International Cancer Institute · Osaka, JapanNot yet recruiting→Recruiting
    Show 6 added (6 Japan)
    • National Cancer Center Hospital East · Kashiwa, Japan
    • Kanazawa University Hospital · Kanazawa, Japan
    • Mie University Hospital · Tsu, Japan
    • Tohoku University Hospital · Sendai, Japan
    • Okayama University Hospital · Okayama, Japan
    • Kindai University Hospital · Sakai, Japan
    Start date Aug 18, 2026→Sep 15, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07734116
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Sep 15, 2026
Primary completion
Nov 30, 2029 (estimated)
Completion
Feb 29, 2032 (estimated)
Last update
Oct 6, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745(Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777(Standard)
Project Leader
study director · Ono Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion